Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer
Cell Reports · 2024-02 · 43 (2) · 113684
DOI: 10.1016/j.celrep.2024.113684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024-02. Verfasst von Amir Hosseini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Ludwig Institute for Cancer Research, Nuffield Department of…. Hauptthemen laut MEDLINE: Retroelements, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Horizon 2020 Framework Programme, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Viral mimicry describes the immune response induced by endogenous stimuli such as double-stranded RNA (dsRNA) from endogenous retroelements. Activation of viral mimicry has the potential to kill cancer cells or augment anti-tumor immune responses. Here, we systematically identify mechanisms of viral mimicry adaptation associated with cancer cell dependencies. Among the top hits is the RNA decay protein XRN1 as an essential gene for the survival of a subset of cancer cell lines. XRN1 dependency is mediated by mitochondrial antiviral signaling protein and protein kinase R activation and is associated with higher levels of cytosolic dsRNA, higher levels of a subset of Alus capable of forming dsRNA, and higher interferon-stimulated gene expression, indicating that cells die due to induction of viral mimicry. Furthermore, dsRNA-inducing drugs such as 5-aza-2'-deoxycytidine and palbociclib can generate a synthetic dependency on XRN1 in cells initially resistant to XRN1 knockout. These results indicate that XRN1 is a promising target for future cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Pathology, Oslo University Hospital-Rikshospitalet, 0372 Oslo, Norway.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
- Pfizer Centers for Therapeutic Innovation, South San Francisco, CA 94080, USA.
- Laboratoire de Physique de l'Ecole Normale Supérieure, PSL & CNRS UMR8063, Sorbonne Université, Université de Paris, Paris, France.
Förderung
- NCI NIH HHS
- Horizon 2020 Framework Programme
- Canadian Institutes of Health Research
- Pfizer
- Canada Research Chairs
- Terry Fox Research Institute
- Princess Margaret Cancer Foundation
Zitieren
APA
Hosseini, A., Lindholm, H. T., Chen, R., Mehdipour, P., Marhon, S. A., Ishak, C. A., Moore, P. C., Classon, M., Di Gioacchino, A., Greenbaum, B., & De Carvalho, D. D. (2024). Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell Reports, 43(2), 113684. https://doi.org/10.1016/j.celrep.2024.113684
Vancouver
Hosseini A, Lindholm HT, Chen R, Mehdipour P, Marhon SA, Ishak CA, et al. Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. Cell Reports. 2024;43(2):113684. doi:10.1016/j.celrep.2024.113684
BibTeX
@article{Hosseini2024,
author = {Hosseini, Amir and Lindholm, Håvard T and Chen, Raymond and Mehdipour, Parinaz and Marhon, Sajid A and Ishak, Charles A and Moore, Paul C and Classon, Marie and Di Gioacchino, Andrea and Greenbaum, Benjamin and De Carvalho, Daniel D},
title = {Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer},
journal = {Cell Reports},
year = {2024},
volume = {43},
number = {2},
pages = {113684},
doi = {10.1016/j.celrep.2024.113684}
}
EUVIMED